Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.26
NAS:DRRX's Cash-to-Debt is ranked lower than
61% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. NAS:DRRX: 1.26 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:DRRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.68  Med: 21.02 Max: No Debt
Current: 1.26
Equity-to-Asset 0.21
NAS:DRRX's Equity-to-Asset is ranked lower than
93% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:DRRX: 0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:DRRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.41 Max: 0.96
Current: 0.21
0.07
0.96
Piotroski F-Score: 2
Altman Z-Score: -14.60
Beneish M-Score: -3.77
WACC vs ROIC
13.11%
-629.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -230.76
NAS:DRRX's Operating Margin % is ranked lower than
90% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. NAS:DRRX: -230.76 )
Ranked among companies with meaningful Operating Margin % only.
NAS:DRRX' s Operating Margin % Range Over the Past 10 Years
Min: -230.76  Med: -108.14 Max: 30.25
Current: -230.76
-230.76
30.25
Net Margin % -246.05
NAS:DRRX's Net Margin % is ranked lower than
90% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. NAS:DRRX: -246.05 )
Ranked among companies with meaningful Net Margin % only.
NAS:DRRX' s Net Margin % Range Over the Past 10 Years
Min: -246.05  Med: -116.24 Max: 30.53
Current: -246.05
-246.05
30.53
ROE % -263.22
NAS:DRRX's ROE % is ranked lower than
97% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. NAS:DRRX: -263.22 )
Ranked among companies with meaningful ROE % only.
NAS:DRRX' s ROE % Range Over the Past 10 Years
Min: -297.22  Med: -100.4 Max: 81.39
Current: -263.22
-297.22
81.39
ROA % -77.53
NAS:DRRX's ROA % is ranked lower than
93% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. NAS:DRRX: -77.53 )
Ranked among companies with meaningful ROA % only.
NAS:DRRX' s ROA % Range Over the Past 10 Years
Min: -79.08  Med: -46.17 Max: 34.06
Current: -77.53
-79.08
34.06
ROC (Joel Greenblatt) % -1330.35
NAS:DRRX's ROC (Joel Greenblatt) % is ranked lower than
91% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. NAS:DRRX: -1330.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:DRRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1371.98  Med: -742.02 Max: 500.45
Current: -1330.35
-1371.98
500.45
3-Year Revenue Growth Rate -11.00
NAS:DRRX's 3-Year Revenue Growth Rate is ranked lower than
86% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. NAS:DRRX: -11.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:DRRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.5  Med: 3.4 Max: 234
Current: -11
-35.5
234
3-Year EBITDA Growth Rate 6.10
NAS:DRRX's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. NAS:DRRX: 6.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:DRRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -35  Med: -5.6 Max: 39.7
Current: 6.1
-35
39.7
3-Year EPS without NRI Growth Rate 7.40
NAS:DRRX's 3-Year EPS without NRI Growth Rate is ranked higher than
51% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. NAS:DRRX: 7.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:DRRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -28.3  Med: -9.4 Max: 27.7
Current: 7.4
-28.3
27.7
GuruFocus has detected 4 Warning Signs with Durect Corp $NAS:DRRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:DRRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DRRX Guru Trades in Q1 2016

First Eagle Investment 14,381,546 sh (+2.13%)
Robert Bruce 713,609 sh (unchged)
Jim Simons Sold Out
» More
Q2 2016

DRRX Guru Trades in Q2 2016

First Eagle Investment 19,881,546 sh (+38.24%)
Robert Bruce 713,609 sh (unchged)
» More
Q3 2016

DRRX Guru Trades in Q3 2016

First Eagle Investment 22,381,546 sh (+12.57%)
Robert Bruce 713,609 sh (unchged)
» More
Q4 2016

DRRX Guru Trades in Q4 2016

First Eagle Investment 22,431,546 sh (+0.22%)
Robert Bruce 498,112 sh (-30.20%)
» More
» Details

Insider Trades

Latest Guru Trades with DRRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:ACNNF, NAS:STDY, OTCPK:ELTP, NAS:CPIX, NAS:ARLZ, NAS:MSLI, OTCPK:HYYDF, NAS:TYHT, NAS:ADMP, NAS:AGRX, OTCPK:ZOMHF, NAS:EPIX, OTCPK:OWCP, OTCPK:CPHRF, NAS:CPRX, NAS:NEOS, NAS:SMMT, NAS:SPHS, OTCPK:BIOYF, OTCPK:OGRMF » details
Traded in other countries:DC8.Germany,
Headquarter Location:USA
Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and Drug Delivery Programs.

Durect Corp was incorporated in Delaware in February 1998. The company is a biopharmaceutical company with research and development programs broadly falling into two categories: (i) new chemical entities derived from its Epigenetic Regulator Program, in which company attempts to discover and develop molecules which have not previously been approved and marketed as therapeutics, and (ii) Drug Delivery Programs, in which company applies its formulation expertise and technologies largely to active pharmaceutical ingredients. It also also manufactures and sells osmotic pumps used in laboratory research and design, develop and manufacture a wide range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

Ratios

vs
industry
vs
history
PB Ratio 14.66
DRRX's PB Ratio is ranked lower than
94% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. DRRX: 14.66 )
Ranked among companies with meaningful PB Ratio only.
DRRX' s PB Ratio Range Over the Past 10 Years
Min: 1.68  Med: 8.71 Max: 39.79
Current: 14.66
1.68
39.79
PS Ratio 8.23
DRRX's PS Ratio is ranked lower than
81% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DRRX: 8.23 )
Ranked among companies with meaningful PS Ratio only.
DRRX' s PS Ratio Range Over the Past 10 Years
Min: 0.91  Med: 8.85 Max: 20.84
Current: 8.23
0.91
20.84
EV-to-EBIT -4.44
DRRX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. DRRX: -4.44 )
Ranked among companies with meaningful EV-to-EBIT only.
DRRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.1  Med: -6.7 Max: 5.8
Current: -4.44
-18.1
5.8
EV-to-EBITDA -4.48
DRRX's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. DRRX: -4.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
DRRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20  Med: -7 Max: 5.5
Current: -4.48
-20
5.5
Current Ratio 1.13
DRRX's Current Ratio is ranked lower than
85% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. DRRX: 1.13 )
Ranked among companies with meaningful Current Ratio only.
DRRX' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 5.46 Max: 25.7
Current: 1.13
1.13
25.7
Quick Ratio 1.00
DRRX's Quick Ratio is ranked lower than
79% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. DRRX: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
DRRX' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 4.96 Max: 25.07
Current: 1
1
25.07
Days Inventory 269.15
DRRX's Days Inventory is ranked lower than
90% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. DRRX: 269.15 )
Ranked among companies with meaningful Days Inventory only.
DRRX' s Days Inventory Range Over the Past 10 Years
Min: 215.56  Med: 250.47 Max: 353.27
Current: 269.15
215.56
353.27
Days Sales Outstanding 30.03
DRRX's Days Sales Outstanding is ranked higher than
86% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. DRRX: 30.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.9  Med: 41.17 Max: 55.94
Current: 30.03
14.9
55.94
Days Payable 143.93
DRRX's Days Payable is ranked higher than
83% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. DRRX: 143.93 )
Ranked among companies with meaningful Days Payable only.
DRRX' s Days Payable Range Over the Past 10 Years
Min: 55.54  Med: 104.55 Max: 207.57
Current: 143.93
55.54
207.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.90
DRRX's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. DRRX: -7.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DRRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.5  Med: -7.8 Max: -2.1
Current: -7.9
-28.5
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 29.33
DRRX's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. DRRX: 29.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DRRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.53  Med: 12.11 Max: 172.5
Current: 29.33
2.53
172.5
Price-to-Tangible-Book 88.00
DRRX's Price-to-Tangible-Book is ranked lower than
98% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. DRRX: 88.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DRRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.78  Med: 8.78 Max: 95.71
Current: 88
1.78
95.71
Price-to-Median-PS-Value 0.93
DRRX's Price-to-Median-PS-Value is ranked higher than
53% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. DRRX: 0.93 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DRRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 1.3 Max: 12.5
Current: 0.93
0.17
12.5
Earnings Yield (Greenblatt) % -22.63
DRRX's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. DRRX: -22.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DRRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -23.81  Med: 30.1 Max: 48.9
Current: -22.63
-23.81
48.9

More Statistics

Revenue (TTM) (Mil) $14.03
EPS (TTM) $ -0.25
Beta1.85
Short Percentage of Float2.13%
52-Week Range $0.82 - 2.00
Shares Outstanding (Mil)141.89

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 14 13 17
EPS ($) -0.23 -0.14 -0.12
EPS without NRI ($) -0.23 -0.14 -0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for DRRX

Headlines

Articles On GuruFocus.com
DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatit Apr 24 2017 
DURECT to Present Clinical Data at the International Liver Congress™ 2017 Apr 17 2017 
DURECT to Present at the H.C. Wainwright NASH Investor Conference Apr 03 2017 
Jean-Marie Eveillard and Arnold Van Den Berg Raise Stakes in Small-Cap Stocks Mar 24 2015 
Jean-Marie Eveillard Ups Stake in Pharma Company Durect Mar 23 2015 
Durect Corp. Reports Operating Results (10-Q) Nov 04 2010 
Durect Corp. Reports Operating Results (10-Q) Aug 05 2010 
Opportunistic Coat-tailing Jan 05 2010 
Durect Corp. Reports Operating Results (10-Q) Nov 02 2009 
Durect Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
ETFs with exposure to DURECT Corp. : April 27, 2017 Apr 27 2017
The Life Sciences Report Examines How Trial Results Set Up DURECT Corp. for 'Exciting Year' Apr 27 2017
NASH: The next untapped pharma market gives investors many options Apr 24 2017
DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic... Apr 24 2017
DURECT to Present Clinical Data at the International Liver Congress™ 2017 Apr 17 2017
DURECT to Present at the H.C. Wainwright NASH Investor Conference Apr 03 2017
The Life Sciences Report Interviews DURECT Corp. President and CEO James Brown Mar 30 2017
ETFs with exposure to DURECT Corp. : March 27, 2017 Mar 27 2017
DURECT Corp. :DRRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and... Mar 20 2017
Durect reports 4Q loss Mar 14 2017
DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of... Mar 14 2017
DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call Feb 24 2017
DRRX: Update on DUR-928 Development Program Feb 15 2017
DURECT Corporation Announces Update on DUR-928 Development Program Jan 30 2017
How DURECT Corporation (DRRX) Stacks Up Against Its Peers Dec 15 2016
ETFs with exposure to DURECT Corp. : December 9, 2016 Dec 09 2016
ETF’s with exposure to DURECT Corp. : November 3, 2016 Nov 03 2016
The Life Sciences Report Examines Why the Election Is Not as Relevant to Drug Stocks as You Might... Nov 03 2016
DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 2, 2016 Nov 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)